Amneal Pharmaceuticals 8-K Report: Key Insights from January 2025 Filing
From the provided section of the financial report, here are the key pieces of information and insights:
- Entity Information:
- Company Name: Amneal Pharmaceuticals, Inc.
- CIK: 0001723128
- SEC Central Index Key: 001-38485
- EIN: 93-4225266
- Address: 400 Crossing Blvd, Bridgewater, NJ 08807
- Phone Number: 908-947-3120
- Filing Details:
- Filing Type: 8-K
- Filing Date: January 15, 2025
- Period Covered: August 4, 2023 (specific date only)
- Securities Information:
- Class of Stock: Class A Common Stock
- Par Value: $0.01 per share
- Stock Symbol: AMRX
- Exchange: NASDAQ
- Context Information:
- Schema Reference: The filing refers to an XBRL schema file (amrx-20250115.xsd), indicating that it uses XBRL for reporting purposes.
Insights:
- The filing is an 8-K, which typically reports unscheduled material events or corporate changes that are important to shareholders. The specific event or change that prompted this filing is not detailed in the provided text.
- The date of the report indicates that it may pertain to a significant event that occurred on August 4, 2023, which could be important for stakeholders to review further.
- Amneal Pharmaceuticals is engaged in the pharmaceutical industry, and investors may want to pay attention to the content of the 8-K for any developments impacting the company's operations, financial position, or stock performance.